Invesco Ltd. Has $951,000 Holdings in CRISPR Therapeutics AG $CRSP

Key Points

• Invesco Ltd. reduced its holdings in CRISPR Therapeutics AG by 17.3% during the first quarter, now owning 27,957 shares valued at approximately $951,000.
• Major institutional investors, including Vanguard Group and IQ EQ Fund Management, have increased their stakes in CRISPR Therapeutics, with institutional ownership reaching 69.20% of the stock.
• CRISPR Therapeutics reported adjusted earnings per share of ($1.29), surpassing analysts' expectations and showing a year-over-year revenue increase of 72.5%, despite the company facing a negative net margin of 1,229.43%.

Invesco Ltd. decreased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 17.3% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 27,957 shares of the company's stock after selling 5,833 shares during the period. Invesco Ltd.'s holdings in CRISPR Therapeutics were worth $951,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. ARK Investment Management LLC increased its holdings in shares of CRISPR Therapeutics by 13.3% during the 1st quarter. ARK Investment Management LLC now owns 10,165,400 shares of the company's stock valued at $345,929,000 after acquiring an additional 1,192,336 shares during the last quarter. B & T Capital Management DBA Alpha Capital Management bought a new stake in CRISPR Therapeutics during the 1st quarter valued at approximately $416,000. Cambridge Investment Research Advisors Inc. boosted its stake in CRISPR Therapeutics by 14.3% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 39,189 shares of the company's stock valued at $1,334,000 after purchasing an additional 4,914 shares during the period. Green Alpha Advisors LLC boosted its stake in CRISPR Therapeutics by 132.9% during the 1st quarter. Green Alpha Advisors LLC now owns 57,361 shares of the company's stock valued at $1,952,000 after purchasing an additional 32,732 shares during the period. Finally, Vanguard Group Inc. boosted its stake in CRISPR Therapeutics by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 1,769,709 shares of the company's stock valued at $60,223,000 after purchasing an additional 33,711 shares during the period. Institutional investors and hedge funds own 69.20% of the company's stock.

Insider Buying and Selling at CRISPR Therapeutics

In related news, Director Simeon George bought 989,812 shares of the company's stock in a transaction dated Wednesday, July 16th. The stock was acquired at an average cost of $52.03 per share, with a total value of $51,499,918.36. Following the acquisition, the director owned 1,730,179 shares in the company, valued at approximately $90,021,213.37. This represents a 133.69% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 4.10% of the company's stock.

CRISPR Therapeutics Stock Up 4.0%

CRISPR Therapeutics stock traded up $2.12 during trading hours on Friday, hitting $54.86. The stock had a trading volume of 2,731,024 shares, compared to its average volume of 2,230,674. The company has a 50-day moving average of $56.36 and a two-hundred day moving average of $45.43. The company has a market cap of $4.99 billion, a PE ratio of -10.10 and a beta of 1.81. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $71.13.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported ($1.29) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.18. The firm had revenue of $0.89 million during the quarter, compared to analysts' expectations of $6.44 million. CRISPR Therapeutics had a negative return on equity of 20.05% and a negative net margin of 1,229.43%.The company's revenue for the quarter was up 72.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.49) EPS. As a group, analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Analysts Set New Price Targets

CRSP has been the subject of several recent analyst reports. Piper Sandler restated an "overweight" rating and set a $105.00 target price on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Chardan Capital restated a "buy" rating and set a $82.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, August 5th. Royal Bank Of Canada increased their target price on CRISPR Therapeutics from $38.00 to $42.00 and gave the company a "sector perform" rating in a research note on Tuesday, August 5th. JMP Securities restated a "market outperform" rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Finally, Wall Street Zen upgraded CRISPR Therapeutics to a "sell" rating in a research note on Friday, May 16th. Nine analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, CRISPR Therapeutics currently has a consensus rating of "Hold" and a consensus price target of $71.60.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.